Shanghai Henlius Biotech, Inc. (HKG:2696)

Shanghai Henlius Biotech Revenue

Shanghai Henlius Biotech had revenue of 3.59B CNY in the half year ending June 30, 2026, with 30.67% growth. This brings the company's total for the last twelve months to 7.44B, up 28.24% year-over-year. In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B with 16.46% growth. That makes Shanghai Henlius Biotech the 7,208th largest company in the world by revenue and 459th in Hong Kong.

• Revenue (ttm): 7.44B CNY
• Revenue Growth: +28.24%
• P/S Ratio: 3.32
• Revenue / Employee: 1.82M CNY
• Employees: 4,082
• Market Cap: 29.28B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• Chinese Mainland 5.78B 86.7%
• North America 465.47M 7.0%
• Europe 275.80M 4.1%
• Asia Pacific (Excluding Chinese Mainland) 116.01M 1.7%
• South America 27.58M 0.4%

Fiscal year ended Dec 31, 2025 See the full Shanghai Henlius Biotech breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.67B	942.18M	16.46%
Dec 31, 2024	5.72B	329.54M	6.11%
Dec 31, 2023	5.39B	2.18B	67.82%
Dec 31, 2022	3.21B	1.53B	91.07%
Dec 31, 2021	1.68B	1.09B	186.34%

Data Source: S&P Global Market Intelligence Last updated: Sep 24, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error